Box, Inc. (NYSE: BOX) confirmed that it has collaborated with Polpharma Biologics. As per the partnership, Polpharma Biologics has chosen Box to enable secure cloud content management and collaboration as part of the relationship. Polpharma Biologics which has earned a reputation as a European biotechnology company based in Poland and the Netherlands is choosing Box as their single, integrated cloud solution to centralize regulated, sensitive content.
For the entire spectrum of Content Cloud services, Polpharma Biologics chose Box Enterprise Plus. Box GxP Validation is one of the capabilities that allow you to handle both unregulated and regulated information in the cloud. Polpharma Biologics compared the advantages of Box GxP for rapid validation to existing systems like Microsoft SharePoint.
GxP Validation was first announced by Box in 2018 as a novel solution to ensuring GxP compliance in the cloud. With today’s announcement, Polpharma Biologics joins a famous increasing of renowned life science and biotechnology companies, including AstraZeneca, Amgen, and Allergan, that are using Box to power new ways of working.
Box Consulting is another function that helps accelerate Box adoption and roll-out to teams across the company, such as Research & Development, Regulatory Affairs, and Quality Assurance. Polpharma Biologics creates biosimilar medications to help patients have access to treatments they need. As a biotech company, we understand how critical it is to maintain quality in all aspects of our operations.
Furthermore, Box stated that the past two years have demonstrated the need for cross-institutional research and industry collaboration in the medication development and manufacturing process. Organizations are turning to technology platforms to accelerate and standardize investments in R&D and manufacturing without losing security and compliance when heavily regulated IP and research data are required for the next breakthrough therapy.